製薬の市場規模、シェア、成長分析：製品別、経済規模別、適応症別、流通チャネル別、地域別 - 産業予測 2025～2032年

製薬の世界市場規模は2023年に1兆8,000億米ドルと評価され、2024年の1兆8,900億米ドルから2032年には2兆8,400億米ドルに成長し、予測期間（2025-2032年）のCAGRは5.2％で成長する見通しです。

世界の製薬市場は、非感染性疾患の蔓延、平均寿命の伸び、1人当たり所得の増加、政府ヘルスケア支出の増加など、いくつかの極めて重要な要因によって大きく成長する見通しです。人口の高齢化は、患者の予後改善を目的とした先進的かつ革新的な医療製品に対する需要をさらに高めています。新製品の上市が盛んで、今後5年間で約300の新薬が上市される見込みであり、特に専門薬、ニッチ薬、希少薬のカテゴリーで顕著な拡大が見込まれ、1,960億米ドルの支出が予測されています。しかし、市場は既存企業間の熾烈な競合と、未開発のビジネスチャンスを狙う新規参入企業の着実な流入によって特徴づけられ、ダイナミックで進化する市場情勢を形成しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

製薬市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 製薬
  • 特許取得済みの処方薬
  • ジェネリック処方薬
  • 市販薬
• その他のヘルスケア業界
  • 医療機器
  • 臨床診断
  • その他

製薬市場規模：経済規模別& CAGR（2025-2032）

• 市場概要
• ティア1
• ティア2
• ティア3

製薬市場規模：適応症別& CAGR（2025-2032）

• 市場概要
• 生活習慣病
• がんと自己免疫疾患
• 感染症
• その他

製薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院
• オンラインストア
• 小売薬局
• その他

製薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Sanofi S.A.（France）
• AstraZeneca PLC（UK）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• Abbott Laboratories（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Cipla Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Lupin Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Valeant Pharmaceuticals International（Canada）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Sinopharm（China）
• Shanghai Fosun Pharmaceutical（Group）Co., Ltd（China）
• EMS S.A.（Brazil）

結論と推奨事項

Global Pharmerging Market size was valued at USD 1.8 trillion in 2023 and is poised to grow from USD 1.89 trillion in 2024 to USD 2.84 trillion by 2032, growing at a CAGR of 5.2% during the forecast period (2025-2032).

The global pharmerging market is poised for significant growth driven by several pivotal factors including the increasing prevalence of non-communicable diseases, rising life expectancy, heightened per capita income, and escalated government healthcare spending. The aging population further intensifies the demand for advanced and innovative medical products aimed at improved patient outcomes. Proliferation in new product launches, with approximately 300 new drugs expected in the next five years-especially in specialty, niche, and orphan categories-signals a noteworthy expansion, projected to generate USD 196 billion in spending. However, the market is marked by fierce competition among established players and a steady influx of new entrants targeting untapped opportunities, shaping a dynamic and evolving landscape ahead.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmerging market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmerging Market Segmental Analysis

Global Pharmerging Market is segmented by Product, Economy, Indication, Distribution Channel and region. Based on Product, the market is segmented into Pharmaceutical and Other Healthcare Verticals. Based on Economy, the market is segmented into Tier-1, Tier-2 and Tier-3. Based on Indication, the market is segmented into Lifestyle Diseases, Cancer & Autoimmune Diseases, Infectious Diseases and Others. Based on Distribution Channel, the market is segmented into Hospitals, online stores, retail pharmacies and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharmerging Market

The global pharmerging market is propelled by several key factors, including the high incidence of chronic diseases, increased awareness among consumers regarding early disease detection and treatment options, and ongoing advancements in research and development. Additionally, rising life expectancy plays a significant role in this market's growth. Government initiatives in emerging economies like India, China, and Indonesia further enhance consumer awareness about pharmaceutical innovations. The proliferation of insurance companies offering diverse coverage to reduce the financial burden of pharmerging treatments also boosts demand for pharmaceuticals worldwide. A pertinent example is Hexvix, which has been added to the 2022 Lecheng Global Specialty Drug Insurance Drug List for bladder cancer diagnosis.

Restraints in the Global Pharmerging Market

The growth of the global Pharmerging market may face significant challenges due to concerns related to intellectual property protection and socio-political factors affecting cross-border transactions. Additionally, stringent price controls could lead to value erosion, further restraining market expansion in the upcoming years. Moreover, the stringent approval processes imposed by government regulatory bodies for the introduction and use of pharmaceuticals can hinder market growth throughout the forecast period. These factors collectively pose substantial risks that could limit the potential development and profitability of the Pharmerging market in a fluctuating global landscape.

Market Trends of the Global Pharmerging Market

The global pharmerging market is witnessing robust growth driven by heightened R&D activities in biotechnology, immunology, and oncology sectors, which are reshaping healthcare paradigms. Major pharmaceutical companies are prioritizing the development of innovative technologies that enhance user convenience and improve patient outcomes. Additionally, the rapid increase in global population, coupled with rising disease prevalence, is further propelling demand for advanced healthcare solutions. This synergy of innovation and necessity is fostering an environment ripe for investment and expansion in emerging markets, making them pivotal players in the global pharmaceutical landscape as they seek to address both local and global health challenges.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pharmerging Market Size by Product & CAGR (2025-2032)

• Market Overview
• Pharmaceutical
  • Patented Prescription Drugs
  • Generic Prescription Drugs
  • OTC Drugs
• Other Healthcare Verticals
  • Medical Device
  • Clinical Diagnostics
  • Others

Global Pharmerging Market Size by Economy & CAGR (2025-2032)

• Market Overview
• Tier-1
• Tier-2
• Tier-3

Global Pharmerging Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Lifestyle Diseases
• Cancer & Autoimmune Diseases
• Infectious Diseases
• Others

Global Pharmerging Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals
• online stores
• retail pharmacies
• others

Global Pharmerging Market Size & CAGR (2025-2032)

• North America (Product, Economy, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Product, Economy, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Economy, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Economy, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Economy, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinopharm (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMS S.A. (Brazil)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations